The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Phase I study of ven/aza maintenance therapy following ven/FluBu2 RIC alloSCT in high-risk MDS/AML
Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, shares the findings of a Phase I trial assessing the safety and efficacy of venetoclax (ven)/azacitidine (aza) maintenance therapy following ven/fludarabine/busulfan (FluBu2) reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (alloSCT) in patients with high-risk acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS; NCT03613532). This trial aimed to address relapse risk after alloSCT in this high-risk patient population. Overall, ven/aza maintenance therapy appeared to be effective and well-tolerated, with low rates of infections and graft-versus-host disease (GvHD). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
AbbVie, Astellas, and Takeda: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Other: Advisory Board; AbbVie, Genentech, AstraZeneca, Prelude and Pfizer: Other: Clinical trial support (institutional); Research Funding; AbbVie: Research Funding.
